论文部分内容阅读
背景与目的:肿瘤标志物检测是肿瘤血清学诊断的主要方法之一,但肿瘤标志物的阳性诊断率较低。本研究旨在分析肿瘤蛋白芯片C12在结直肠癌(colorectal cancer,CRC)诊断中的价值。方法:分析总结130例CRC初治患者12种肿瘤标志物的检测结果,找出与CRC相关性最强的肿瘤标志物,计算各标志物组检测对提高诊断率的作用。结果:C12对本组CRC患者的总体诊断率是42.3%,对Ⅰ、Ⅱ、Ⅲ、Ⅳ期患者的诊断率分别是13.6%、39.5%、38.2%和68.8%;对Ⅳ期患者的诊断率显著高于Ⅰ期患者(P<0.001);癌胚抗原(carcioembryonic antigen,CEA)的阳性率最高,达35.4%,与之相比,阳性率最高的5种标志物的任何组合方式(2、3、4、5种标志物的组合)均不能提高诊断率,但四项指标联合检测CEA+前列腺特异性抗原(free prostate specific antigen,f-PSA)+肿瘤抗原(cancer antigen,CA)125+CA242或CEA+CA19-9+CA125+f-PSA足以替代12项指标联合检测。结论:C12对诊断中晚期CRC有一定价值,但对早期CRC的灵敏度不高。
BACKGROUND & OBJECTIVE: Tumor marker detection is one of the major methods of tumor serological diagnosis, but the positive rate of tumor markers is low. This study aimed to analyze the value of oncoprotein C12 in the diagnosis of colorectal cancer (CRC). Methods: To summarize the results of 12 kinds of tumor markers in 130 cases of primary CRC, find out the most relevant tumor markers in CRC, and calculate the effect of each marker group to improve the diagnosis rate. Results: The overall diagnosis rate of C12 in this group was 42.3%, and the diagnostic rates of patients with stage I, II, III and IV were 13.6%, 39.5%, 38.2% and 68.8%, respectively. The diagnosis rate of patients with stage IV was significantly (P <0.001). The highest positive rate of carcioembryonic antigen (CEA) was 35.4%, compared with any combination of the five markers with the highest positive rate (2,3 , And no combination of 4 and 5 markers), but no correlation was found between the four markers of CEA + free prostate specific antigen (f-PSA) + cancer antigen (CA) 125 + CA242 or CEA + CA19-9 + CA125 + f-PSA sufficient to replace the 12 indicators of joint testing. Conclusion: C12 has some value in the diagnosis of advanced CRC, but its sensitivity to early CRC is not high.